Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Skye Bioscience, Inc. Logo
Clinical-stage biotech developing a CB1-inhibiting antibody for obesity and metabolic diseases.
United States of America SKYE
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
SOLENO THERAPEUTICS INC Logo
Develops novel therapeutics for rare diseases like Prader-Willi syndrome.
United States of America SLNO
Sol-Gel Technologies Ltd. Logo
Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.
United States of America SLGL
Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.